$11.80
1.67% day before yesterday
Nasdaq, Dec 27, 10:01 pm CET
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Roivant Sciences Stock price

$11.80
-0.89 7.01% 1M
+1.23 11.64% 6M
+0.57 5.08% YTD
+0.22 1.90% 1Y
-0.02 0.17% 3Y
+2.45 26.20% 5Y
+2.45 26.20% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.20 1.67%
ISIN
BMG762791017
Symbol
ROIV
Sector
Industry

Key metrics

Market capitalization $8.59b
Enterprise Value $3.68b
P/E (TTM) P/E ratio 2.09
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 29.28
P/S ratio (TTM) P/S ratio 68.35
P/B ratio (TTM) P/B ratio 1.68
Revenue growth (TTM) Revenue growth 21.84%
Revenue (TTM) Revenue $125.68m
EBIT (operating result TTM) EBIT $-1.13b
Free Cash Flow (TTM) Free Cash Flow $-781.21m
Cash position $5.39b
EPS (TTM) EPS $5.66
P/E forward negative
P/S forward 93.27
EV/Sales forward 39.95
Short interest 8.09%
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Roivant Sciences forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Roivant Sciences forecast:

Buy
90%
Hold
10%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
126 126
22% 22%
100%
- Direct Costs 21 21
42% 42%
16%
121 121
77% 77%
96%
- Selling and Administrative Expenses 711 711
26% 26%
566%
- Research and Development Expense 520 520
1% 1%
414%
-1,115 -1,115
10% 10%
-887%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -1,126 -1,126
8% 8%
-896%
Net Profit 4,810 4,810
590% 590%
3,827%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Positive
Seeking Alpha
25 days ago
Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder va...
Negative
Reuters
26 days ago
Roivant said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of lung disease.
Neutral
Seeking Alpha
about 2 months ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimmer - Chief Executive Officer, Priovant Conference Call Participants Louise Chen - Cantor Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Andy Chen - Wolfe Research Douglas Tsao - H.C.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 908
Founded 2014
Website www.roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today